US Broker Ratings

ResMed Inc. (RMD) Stock Analysis: Exploring Growth Potential and Analyst Ratings

ResMed Inc. (NYSE: RMD), a prominent player in the healthcare sector, continues to capture investor attention with its robust market presence and innovative product offerings. With a market capitalization of..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: Navigating a 4.33% Upside Potential with Robust Growth

Thermo Fisher Scientific Inc (NYSE: TMO) continues to solidify its position as a leader in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of..

Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield

Investors looking at Bristol-Myers Squibb Company (NYSE: BMY) are presented with a unique opportunity within the healthcare sector, especially given its recent financial metrics and analyst ratings. With a market..

GSK plc (GSK) Stock Analysis: Analyst Ratings Reveal a Cautious Outlook Amid Solid Dividend Yield

GSK plc (GSK), a titan in the healthcare sector, stands as a prominent player in the drug manufacturing industry with a market capitalization of $88.28 billion. Headquartered in London, this..

Vertex Pharmaceuticals (VRTX) Investor Outlook: Analyzing a 15% Upside Potential

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a powerhouse in the biotechnology sector, with a particular focus on transformative therapies for cystic fibrosis (CF). With a robust market capitalization of..

Abbott Laboratories (ABT) Stock Analysis: Evaluating a 12.33% Potential Upside for Investors

Abbott Laboratories (NYSE: ABT) stands as a stalwart in the healthcare sector, particularly in the medical devices industry. With a substantial market capitalization of $223.72 billion, Abbott is a heavy..

Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator with a 41.82% Upside Potential

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, has captured investor attention with its promising pipeline and impressive stock performance. Specializing in developing targeted therapies for various solid tumors, Celcuity’s..

Septerna, Inc. (SEPN) Stock Analysis: A Biotech Player with 7.47% Upside Potential

Septerna, Inc. (NASDAQ: SEPN), a burgeoning player in the biotechnology industry, has piqued the interest of investors with its innovative approach to drug development, targeting G protein-coupled receptors (GPCRs). Headquartered..

Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation

Precigen, Inc. (NASDAQ: PGEN) stands as a promising player in the biopharmaceutical sector, capturing investor attention with its cutting-edge gene and cell therapy innovations. Specializing in immuno-oncology and autoimmune disorders,..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a Complex Diagnostics Landscape with Strategic Collaborations

Investors looking at Myriad Genetics, Inc. (NASDAQ: MYGN) are peering into a company that stands at the intersection of molecular diagnostics and precision medicine, targeting key areas such as oncology,..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a 107% Potential Upside with a Strong Buy Consensus

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, finds itself at an intriguing juncture with a compelling opportunity for investors seeking exposure to the drug manufacturing sphere,..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: A 31.92% Potential Upside in the Healthcare Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a specialized player in the medical devices industry, is making waves with its innovative solutions for bunion correction and related midfoot deformities. Headquartered in..

Abivax SA (ABVX) Stock Analysis: A 26% Upside Captivates Investor Attention Amid Phase 3 Trials

Abivax SA (ABVX), a prominent player in the biotechnology sector, is catching the eye of investors with its significant 26.20% potential upside, as analysts set their sights on an average..

ATAI Life Sciences N.V. (ATAI) Stock Analysis: Exploring a Potential 107.57% Upside

ATAI Life Sciences N.V. (NASDAQ: ATAI), a pioneering player in the biotechnology sector, is capturing significant attention from investors with its innovative approach to mental health treatments. With a market..

Organogenesis Holdings Inc. (ORGO) Stock Report: Eyeing a Potential 97% Upside with Robust Analyst Ratings

Organogenesis Holdings Inc. (NASDAQ: ORGO), a key player in the regenerative medicine sector, presents an intriguing opportunity for investors with its significant upside potential. Despite recent challenges, analysts maintain a..

Rapport Therapeutics, Inc. (RAPP)

⚠️ No article content returned.

..

MBX Biosciences (MBX): Analyst Ratings Signal 328% Potential Upside for This Biotech Stock

MBX Biosciences, Inc. (NASDAQ: MBX) stands out in the biotechnology sector with a staggering potential upside of 328.47%, according to recent analyst ratings. This clinical-stage biopharmaceutical company, headquartered in Carmel,..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking a 67% Potential Upside Amidst Robust Revenue Growth

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, has recently piqued investor interest with its compelling growth narrative and substantial potential upside. With a market cap of $558.06 million..

Orthofix Medical Inc. (OFIX) Investor Outlook: Exploring a Potential 49% Upside in the Medical Device Sector

Investors looking for opportunities in the healthcare sector may want to take a closer look at Orthofix Medical Inc. (NASDAQ: OFIX), a key player in the medical devices industry. With..

SIGA Technologies Inc. (SIGA) Stock Analysis: A Look at its Impressive 271.90% Revenue Growth

Investors with a keen eye on the healthcare sector, particularly within the niche of specialty and generic drug manufacturing, may find SIGA Technologies Inc. (NASDAQ: SIGA) an intriguing prospect. This..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds